{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.5","upperLimit":"33.1","value":"17.6"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"32.0","value":"15.9"},{"groupId":"OG002","lowerLimit":"18.2","upperLimit":"51.2","value":"34.4"},{"groupId":"OG003","lowerLimit":"2.5","upperLimit":"38.8","value":"15.4"},{"groupId":"OG004","lowerLimit":"29.3","upperLimit":"54.4","value":"42.1"},{"groupId":"OG005","lowerLimit":"22.9","upperLimit":"45.0","value":"33.8"},{"groupId":"OG006","lowerLimit":"18.2","upperLimit":"66.7","value":"43.6"},{"groupId":"OG007","lowerLimit":"13.2","upperLimit":"82.5","value":"53.6"}]}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"28.9","value":"14.1"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"26.7","value":"10.6"},{"groupId":"OG002","lowerLimit":"12.3","upperLimit":"43.5","value":"26.7"},{"groupId":"OG003","lowerLimit":"2.5","upperLimit":"38.8","value":"15.4"},{"groupId":"OG004","lowerLimit":"17.9","upperLimit":"41.2","value":"29.1"},{"groupId":"OG005","lowerLimit":"19.1","upperLimit":"40.4","value":"29.3"},{"groupId":"OG006","lowerLimit":"18.2","upperLimit":"66.7","value":"43.6"},{"groupId":"OG007","lowerLimit":"13.2","upperLimit":"82.5","value":"53.6"}]}],"title":"Week 32"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"15.2","value":"3.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"3.8","upperLimit":"29.9","value":"13.8"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG004","lowerLimit":"11.6","upperLimit":"33.0","value":"21.3"},{"groupId":"OG005","lowerLimit":"13.3","upperLimit":"33.3","value":"22.6"},{"groupId":"OG006","lowerLimit":"1.5","upperLimit":"50.3","value":"18.2"},{"groupId":"OG007","lowerLimit":"1.3","upperLimit":"67.0","value":"26.8"}]}],"title":"Week 56"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"62"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"description":"PFS was defined as the interval of time between the date of the first dose of study treatment and the earliest date of PD or death due to any cause, whichever comes first, as per RECIST v 1.1 criteria. PFS rate at 24, 32 and 56 weeks were estimated. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as a reference, smallest sum of diameters recorded since the treatment started. In addition, the sum must have an absolute increase from nadir of 5 mm. Estimates were calculated with Kaplan-Meier analysis and 95% CIs using the complementary log-log transformation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with rhabdoid tumors (MRT, RTK, ATRT, and selected tumors with rhabdoid features, including SCCOHT, also known as MRTO) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG000","title":"Rhabdoid Tumors: Cohort 1"},{"description":"Participants with relapsed or refractory synovial sarcoma with SS18-SSX rearrangement received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG001","title":"Synovial Sarcoma: Cohort 2"},{"description":"Participants with other INI-1-negative tumors or any solid tumor with EZH2 GOF mutation, including EMPNST, EMC, myoepithelial carcinoma, other INI-1-negative malignant tumors with sponsor approval, any solid tumor with EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG002","title":"Other INI1-negative: Cohort 3"},{"description":"Participants with RMC received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG003","title":"RMC: Cohort 4"},{"description":"Participants with ES received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG004","title":"ES: Cohort 5"},{"description":"Participants with ES undergoing optional tumour biopsy received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG005","title":"ES Paired Biopsy: Cohort 6"},{"description":"Participants with poorly differentiated chordoma (or other chordoma with sponsor approval) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG006","title":"Chordoma: Cohort 7"},{"description":"Participants with ES received tazemetostat 1600 mg QD orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG007","title":"ES 1600 mg: Cohort 8"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who received at least 1 dose of tazemetostat.","reportingStatus":"POSTED","timeFrame":"At Weeks 24, 32 and 56","title":"All Cohorts: Progression-Free Survival (PFS) Rate at Weeks 24, 32 and 56","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}